文献速递免疫规划

在母源抗体存在下接种佐剂修饰活疫苗对犊牛牛呼吸道合胞病毒的保护作用

Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.
PubMed 文献 · Vaccine · 2019-10-24

本研究评估佐剂修饰活病毒(MLV)疫苗在具有明确母源被动免疫的犊牛中的效力。犊牛约1月龄接种,约90天后当BRSV系统抗体≤1:4时攻毒。接种组攻毒后第6、7天体温较低,其他临床体征也较轻;鼻病毒排毒(病毒分离和PCR检测)低3-4倍,接种组排毒峰值在攻毒后第5天,对照组峰值在第6、7天。攻毒后第8天剖检,接种组肺组织PCR病毒检测减少25倍,2头接种犊牛肺组织PCR阴性;剖检时IFA检测BRSV阳性率接种组29.4% vs 对照组87.5%。接种犊牛产生黏膜BRSV IgA应答,攻毒前超过50%接种犊牛有IgA,攻毒后所有接种犊牛均阳性。疫苗还刺激单核细胞产生干扰素γ(IFN-γ)以启动免疫系统。研究表明,佐剂MLV疫苗可通过临床、病毒学和病理学参数提供抗BRSV保护,同时激活黏膜和系统免疫。

要点

  • 接种组攻毒后第6、7天体温较低,其他临床体征也较轻。
  • 接种组鼻病毒排毒低3-4倍,排毒峰值第5天(对照组第6、7天)。
  • 剖检时接种组肺组织PCR病毒检测减少25倍,2头接种犊牛肺组织PCR阴性。

核心结论

  • 佐剂MLV疫苗在母源抗体存在下可提供抗BRSV保护,并激活黏膜和系统免疫。

研究设计与样本

  • 犊牛约1月龄接种佐剂MLV疫苗,约90天后当BRSV系统抗体≤1:4时攻毒。

主要发现

  • 攻毒后第6、7天接种组体温较低,其他临床体征也较轻。
  • 鼻病毒排毒接种组低3-4倍,排毒峰值第5天,对照组峰值第6、7天。
  • 剖检时接种组肺组织PCR病毒检测减少25倍,2头接种犊牛肺组织PCR阴性。
  • 剖检时IFA检测BRSV阳性率接种组29.4% vs 对照组87.5%。
  • 攻毒前超过50%接种犊牛有黏膜BRSV IgA,攻毒后所有接种犊牛均阳性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bovine respiratory syncytial virus (BRSV) is major viral contributor to bovine respiratory disease (BRD). BRD is a major cause of morbidity and mortality in all classes of cattle but particularly young beef and dairy calves. Passive antibodies not only help protect the calf against infection, but may interfere with the immune responses following vaccination. The purpose of this study was to evaluate the efficacy of an adjuvanted modified live virus (MLV) vaccine in the presence of well-defined maternal passive immunity. Calves were vaccinated at approximately 1 month of age and challenged ~90 days later when BRSV systemic antibodies were ≤1:4. Body temperature was lower at 6 and 7 days post challenge and other clinical signs were also lower in the vaccinates. Nasal viral shed was 3-4 times lower in the vaccinated animals as measured by virus isolation and polymerase chain reaction (PCR) and peaked 5 days post challenge compared to the controls (who peaked at days 6 and 7). On day 8 following challenge, animals were necropsied, and lung lobes were scored and tested for virus by PCR and indirect fluorescent assay (IFA). There was a 25-fold reduction in PCR virus detection in vaccinates and two of the vaccinated calves' lungs were PCR negative. Only 29.4% of vaccinated calves were BRSV positive on IFA testing at necropsy, while 87.5% of control calves were BRSV positive. Vaccinated calves developed a mucosal BRSV IgA response with over 50% of the vaccinated calves having IgA prior to challenge and all vaccinated calves were positive following challenge. Additionally, vaccination stimulated the production of Interferon gamma (IFN-γ) in mononuclear cells to prime the immune system. This study established that an adjuvanted MLV vaccine could provide protection against BRSV as measured by clinical, virological, and pathological parameters while also activating both mucosal and systemic immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kolb EA, Buterbaugh RE, Rinehart CL, et al. Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody. Vaccine. 2019. PMID: 31668818. doi:10.1016/j.vaccine.2019.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。